Brendan D. Curti
- Oncology top 0.5%
- Immunology top 1%
- Molecular Biology top 5%
- Pulmonary and Respiratory Medicine top 1%
- Cancer Research top 2%
- Co-authors
- Walter J. UrbaMark B. FariesBruce G. RedmanRonald M. BukowskiKim MargolinGary R. HudesRobert J. MotzerJohn W. Smith
- Topics
- Cancer Immunotherapy and Biomarkers (88 papers)CAR-T cell therapy research (71 papers)Immunotherapy and Immune Responses (57 papers)
- Cited by
- OncologyImmunologyCancer Research
- Partner nations
- United StatesFranceUnited Kingdom
In The Last Decade
Brendan D. Curti
179 papers receiving 6.2k citations
Hit Papers
Peers
Comparison fields: 5 of 119
- Oncology 3.4k
- Immunology 2.4k
- Molecular Biology 2.1k
- Pulmonary and Respiratory Medicine 1.9k
- Cancer Research 935
Countries citing papers authored by Brendan D. Curti
This map shows the geographic impact of Brendan D. Curti's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brendan D. Curti with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brendan D. Curti more than expected).
Fields of papers citing papers by Brendan D. Curti
This network shows the impact of papers produced by Brendan D. Curti. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brendan D. Curti. The network helps show where Brendan D. Curti may publish in the future.
Co-authorship network of co-authors of Brendan D. Curti
This figure shows the co-authorship network connecting the top 25 collaborators of Brendan D. Curti. A scholar is included among the top collaborators of Brendan D. Curti based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brendan D. Curti. Brendan D. Curti is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 2 | |
| 2 | 0 | |
| 3 | 7 | |
| 4 | 6 | |
| 5 | 8 | |
| 6 | 19 | |
| 7 | 114 | |
| 8 | 15 | |
| 9 | 169 | |
| 10 | Initial results of the phase 1 portion of an ongoing phase 1/2 study of RP1 as a single agent and in combination with nivolumab in patients with solid tumors | 1 |
| 11 | 15 | |
| 12 | 4 | |
| 13 | 1 | |
| 14 | 39 | |
| 15 | 88 | |
| 16 | 11 | |
| 17 | 17 | |
| 18 | 13 | |
| 19 | 98 | |
| 20 | 23 |
About Brendan D. Curti
Brendan D. Curti is a scholar working on Oncology, Immunology and Biotechnology, having authored 185 papers that have together received 6.3k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (88 papers), CAR-T cell therapy research (71 papers) and Immunotherapy and Immune Responses (57 papers). The work is most often cited by research in Oncology (3.4k citations), Immunology (2.4k citations) and Cancer Research (935 citations). Brendan D. Curti has collaborated with scholars based in United States, France and United Kingdom. Frequent co-authors include Walter J. Urba, Mark B. Faries, Bruce G. Redman, Ronald M. Bukowski, Kim Margolin, Gary R. Hudes, Robert J. Motzer, John W. Smith, George Wilding and M. Dror Michaelson. Their work appears in journals such as New England Journal of Medicine, JAMA and Nature Communications.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.